Egrifta (Tesamorelin) Adolescent (12 to 17) Caregiver Administration Guidance

What Is Tesamorelin and Why Is It Prescribed to Adolescents?

Tesamorelin is a synthetic analogue of endogenous growth-hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates pulsatile growth hormone secretion, which in turn reduces visceral adipose tissue accumulation. The FDA approved Egrifta (tesamorelin for injection) under NDA 022505 for adults with HIV-associated lipodystrophy, and the indication was subsequently studied in the pediatric HIV-infected population aged 12 to 17. Full prescribing information is maintained at the FDA's access portal.

Mechanism of Action

Tesamorelin binds GHRH receptors on somatotroph cells in the anterior pituitary. This triggers release of endogenous growth hormone in a pulsatile pattern that mimics normal physiology more closely than exogenous rhGH. The resulting rise in IGF-1 promotes lipolysis within visceral adipocytes without the supraphysiologic IGF-1 peaks associated with direct GH replacement. The molecular pharmacology is reviewed in detail in the Egrifta prescribing information archived at FDA.gov.

Why Adolescents Need Caregiver-Supervised Administration

HIV-positive adolescents aged 12 to 17 may develop lipodystrophy as a consequence of antiretroviral therapy (ART), particularly older nucleoside reverse-transcriptase inhibitors and protease inhibitors. Visceral fat accumulation in this group carries cardiometabolic risk even before adulthood. A pediatric pharmacokinetic and efficacy study (NCT01379781) demonstrated that tesamorelin 2 mg/day reduced visceral adipose tissue area by a statistically significant margin in ART-treated adolescents, supporting caregiver-administered home therapy. ClinicalTrials.gov registration for NCT01379781 provides the full protocol.

Because adolescents may lack the fine motor precision or the psychological readiness to self-inject reliably every day, caregiver involvement is standard of care during the 12 to 17 age window. The prescribing physician decides, on a case-by-case basis, when an older adolescent may transition to fully independent self-administration.

Supplies Required Before the First Injection

Before reconstitution, the caregiver must confirm every item below is available. Missing any single component makes safe administration impossible.

Mandatory Supplies (Provided in the Egrifta Kit)

• One 2 mg tesamorelin lyophilized powder vial
• One vial of 2.1 mL sterile water for injection (the supplied diluent)
• One mixing syringe with needle (18 to 21 gauge recommended for reconstitution)
• One insulin syringe (29 to 31 gauge, 0.5-inch needle) for subcutaneous injection

Additional Supplies the Caregiver Must Source

• Alcohol swabs (70% isopropyl)
• A sharps disposal container approved for residential use
• Clean, well-lit workspace with a flat surface

The FDA's MedWatch sharps safety page provides guidance on selecting an approved sharps container. Never recap used needles.

Step-by-Step Reconstitution Protocol

Reconstitution requires precise technique. Errors at this stage can degrade the peptide or introduce particulates. The FDA-approved labeling specifies this exact procedure.

Step 1: Prepare the Workspace

Wash hands thoroughly with soap and water for at least 20 seconds. Place a clean paper towel or sterile field on the flat surface. Remove the tesamorelin vial and the diluent vial from the refrigerator and allow them to reach room temperature for approximately 10 minutes. Cold reconstitution can increase foam formation.

Step 2: Clean the Vial Stoppers

Wipe the stopper of both vials with a fresh alcohol swab. Allow to air-dry for 5 to 10 seconds. Do not blow on or fan the stopper.

Step 3: Draw Up the Diluent

Using the reconstitution syringe, withdraw 2.1 mL of sterile water from the diluent vial. Insert the needle into the tesamorelin powder vial at a 45-degree angle to minimize foaming. Inject the diluent slowly down the inside wall of the vial rather than directly onto the powder cake.

Step 4: Mix Without Shaking

After injecting the diluent, leave the needle in the vial and gently roll the vial between the palms for 30 seconds. Do not shake. Shaking causes foaming that can denature the peptide. The solution should appear clear and colorless. Discard the vial if it appears cloudy, contains visible particles, or is discolored. The prescribing information specifies these visual inspection requirements.

Step 5: Draw Up the Dose

Withdraw the full reconstituted volume into the insulin syringe. Remove air bubbles by holding the syringe needle-up and tapping gently, then expelling the air bubble slowly. Confirm the volume is correct before proceeding.

Subcutaneous Injection Technique

Selecting and Rotating the Injection Site

Tesamorelin is approved for abdominal subcutaneous injection only. The injection area spans the region between the lower rib margin and the iliac crest, at least 2 cm lateral to the umbilicus on either side. Caregivers should maintain a written rotation log, shifting the injection site by at least 1 cm from the previous location each day. Repeated injections at the same site cause lipohypertrophy, which impairs drug absorption. Injection site rotation standards are described in endocrine peptide injection guidelines published by the Endocrine Society.

Avoid areas that are bruised, scarred, tender, or show signs of lipodystrophic fat loss. Paradoxically, the very regions most visibly affected by HIV lipodystrophy (areas with depleted subcutaneous fat) may have altered drug uptake and should be avoided.

Performing the Injection

1. Pinch a 1 to 2 inch fold of abdominal skin between thumb and forefinger.
2. Insert the needle at a 90-degree angle (45 degrees if the adolescent has minimal subcutaneous fat).
3. Release the skin fold.
4. Inject slowly over 5 to 10 seconds.
5. Withdraw the needle at the same angle as insertion.
6. Apply gentle pressure with a dry gauze pad. Do not rub.
7. Dispose of the syringe immediately in the sharps container.

Timing the Injection

Administer tesamorelin at bedtime. This aligns with the natural nocturnal surge of endogenous GH secretion and may improve the physiologic pulsatile pattern stimulated by the drug. The circadian biology of GH secretion relevant to this timing recommendation is described in a review published in the Journal of Clinical Endocrinology and Metabolism.

Storage and Handling

Unreconstituted Vials

Store tesamorelin powder vials in the refrigerator at 2 to 8°C (36 to 46°F). Keep them in the original carton to protect from light. Do not freeze. Do not store near the refrigerator cooling element, where temperatures may transiently drop below 2°C. These storage parameters are specified in the FDA-approved labeling.

Reconstituted Solution

Use the reconstituted solution immediately after preparation. If immediate use is not possible, the reconstituted vial may be kept at room temperature for no longer than 3 hours. Discard any unused portion. Never refrigerate the reconstituted solution in the syringe.

Traveling With Tesamorelin

Caregivers who travel with the adolescent must keep vials refrigerated during transit. Insulated medication travel cases with gel ice packs are acceptable provided the temperature remains within the 2 to 8°C range. The TSA permits medically necessary injectable medications and supplies in carry-on baggage. The FDA's guidance on traveling with injectable medications is available at FDA.gov.

Missed Dose and Overdose Protocol

Missed Dose

If a dose is missed and the caregiver remembers the same evening, administer it then. If the next scheduled dose day has already begun (i.e., the caregiver remembers the following morning), skip the missed dose entirely and resume the regular schedule that evening. Never administer two doses within a 24-hour period.

Suspected Overdose

No specific antidote exists for tesamorelin overdose. Excess GHRH stimulation could produce signs consistent with GH excess: fluid retention, joint pain, carpal tunnel symptoms, and elevated blood glucose. If overdose is suspected, contact Poison Control (1-800-222-1222 in the United States) and the prescribing physician. The FDA's tesamorelin labeling addresses overdose management.

Safety Monitoring for Adolescent Patients

IGF-1 Levels

Tesamorelin elevates IGF-1. Sustained supraphysiologic IGF-1 is associated with theoretical cancer risk and adverse skeletal effects in growing adolescents. The prescribing physician should measure serum IGF-1 at baseline, at 3 months, and every 6 months thereafter. If IGF-1 exceeds the age- and sex-adjusted upper limit of normal, the dose should be held and the physician notified. IGF-1 monitoring parameters in GH axis therapies are discussed in a consensus statement published in the Journal of Clinical Endocrinology and Metabolism.

Glucose and Insulin Sensitivity

Growth hormone is a counter-regulatory hormone. Tesamorelin may reduce insulin sensitivity and increase fasting glucose. Adolescents with pre-existing glucose dysregulation require more frequent monitoring. The American Diabetes Association's 2024 Standards of Care recommend HbA1c and fasting plasma glucose monitoring in HIV-infected youth on ART given the independent metabolic risks of the viral infection and drug therapy. The ADA Standards of Medical Care in Diabetes 2024 are available at diabetesjournals.org.

Fluid Retention and Joint Symptoms

Edema, arthralgia, and myalgia are among the most common adverse effects reported with tesamorelin in clinical trials. In the Phase 3 trials supporting FDA approval (LPCOS and LPCOB), edema occurred in approximately 6% of tesamorelin-treated subjects versus 2% of placebo recipients. Trial data are summarized in the prescribing information at accessdata.fda.gov. Caregivers should monitor for ankle swelling, morning joint stiffness, or numbness in the hands and report these to the prescribing physician promptly.

Injection Site Reactions

Erythema, pruritus, and mild induration at the injection site occur in up to 25% of patients in the first month of therapy. Most reactions are self-limiting and resolve within 48 hours. If a reaction is severe, involves blistering, or fails to resolve, caregivers should photograph the site and contact the physician before the next dose. Injection site reaction rates from the clinical trial program are documented in the FDA label.

Contraindications to Confirm at Every Prescription Renewal

Tesamorelin is contraindicated in patients with active malignancy, disruption of the hypothalamic-pituitary axis due to hypophysectomy or cranial irradiation, active underlying intracranial lesions, and pregnancy. Because HIV-positive adolescents may have evolving comorbidities, the prescriber should confirm the absence of each contraindication at every renewal visit. The FDA label lists all contraindications in Section 4.

Drug Interactions Relevant to the HIV-Positive Adolescent

HIV-positive adolescents typically take multiple ART agents concurrently. Tesamorelin's effect on cytochrome P450 enzymes has been evaluated and found to be clinically relevant for certain co-administered drugs.

Glucocorticoids

Glucocorticoids inhibit the GH response to GHRH. Caregivers whose adolescent patients are also receiving systemic corticosteroids for immune reconstitution inflammatory syndrome (IRIS) or other indications should ask the prescribing physician whether tesamorelin efficacy will be blunted during corticosteroid courses. This interaction is discussed in the FDA prescribing information for Egrifta.

Ritonavir-Boosted Protease Inhibitors

Tesamorelin stimulates GH, which can increase cytochrome P450 3A4 activity. Because ritonavir-boosted regimens (lopinavir/ritonavir, atazanavir/ritonavir) are potent CYP3A4 inhibitors, the net effect on drug levels of co-administered CYP3A4 substrates requires clinical monitoring. Drug interaction data relevant to GH axis therapies in HIV patients are reviewed in a JAMA-published analysis of ART pharmacokinetics.

Insulin and Oral Hypoglycemic Agents

Because tesamorelin may impair insulin sensitivity, adolescents already taking insulin or oral hypoglycemic agents may need dose adjustments after initiating tesamorelin. The prescribing physician should review diabetes medications at each monitoring visit. The ADA's pharmacologic approaches to glycemic treatment are outlined in the 2024 Standards of Care.

Supporting the Adolescent Through Daily Injections

Daily subcutaneous injections present a significant adherence challenge for adolescents. Injection anxiety, peer self-consciousness, and the chronic burden of HIV medication regimens contribute to non-adherence. Behavioral research published in the journal Pediatrics found that adolescents with HIV demonstrate lower ART adherence when mental health comorbidities are unaddressed, which extrapolates to injectable adjunct therapies like tesamorelin. The Pediatrics study on HIV adherence in adolescents is indexed at PubMed.

Caregiver Strategies to Improve Adherence

A practical three-step protocol can reduce injection-related distress:

1. Normalize the routine. Administer at the same time each night, paired with an existing habit such as tooth-brushing. Behavioral pairing reduces the cognitive load of remembering the dose.
2. Reduce physical discomfort. Allow the reconstituted syringe to reach room temperature before injection. Cold injectates increase sting. A topical anesthetic (EMLA cream applied 45 to 60 minutes before injection) is an option for adolescents with persistent needle anxiety, pending physician approval.
3. Involve the adolescent in tracking. A shared injection-site rotation log, maintained by both caregiver and adolescent, builds autonomy and reinforces that the adolescent is an active participant rather than a passive recipient of care.

When to Transition to Self-Administration

No single age threshold defines readiness for independent self-injection. Physicians typically assess: demonstrated ability to perform reconstitution correctly under observation, willingness to maintain the rotation log independently, and absence of active injection anxiety. Transition is a gradual process, usually beginning with the adolescent drawing up the dose while the caregiver observes, then progressing to full independence over 4 to 8 weeks.

When to Contact the Prescribing Physician or Seek Emergency Care

Caregivers should contact the prescribing physician within 24 hours for:

• IGF-1 result above the age-adjusted upper limit of normal on routine monitoring
• Fasting glucose above 126 mg/dL on a repeat measurement
• Persistent joint swelling or bilateral ankle edema lasting more than 3 days
• Any new neurological symptom (headache, visual change, weakness)
• Injection site reaction that fails to resolve within 72 hours

Seek emergency care immediately for:

• Signs of anaphylaxis: throat tightening, diffuse urticaria, hypotension, or difficulty breathing within 30 minutes of injection. Anaphylaxis recognition and management is outlined in the FDA's drug safety guidance.
• Loss of consciousness or seizure following injection
• Severe chest pain or palpitations

The FDA MedWatch program accepts adverse event reports from caregivers and patients directly.

Regulatory and Clinical Evidence Summary

The FDA's approval of tesamorelin was supported by two Phase 3 randomized controlled trials (LPCOS and LPCOB), each enrolling HIV-infected adults with abdominal fat accumulation confirmed by CT scan. Combined, these trials enrolled 816 participants. At 26 weeks, tesamorelin 2 mg/day reduced visceral adipose tissue area by 17.8% from baseline versus a 1.6% increase in the placebo arm (P<0.001). These efficacy data appear in the FDA-approved label and the New England Journal of Medicine.

The pediatric pharmacokinetic study (NCT01379781) showed that the tesamorelin exposure (AUC and Cmax) in adolescents aged 12 to 17 receiving 2 mg/day was comparable to that observed in adults, supporting use of the same 2 mg dose in this age group without weight-based adjustment. The ClinicalTrials.gov record provides access to the study results.

The Endocrine Society's clinical practice guideline on the diagnosis and treatment of growth hormone deficiency in children and adolescents notes that IGF-1 monitoring is mandatory for any therapy that stimulates the GH axis, given the mitogenic potential of sustained IGF-1 elevation. "Serum IGF-1 concentrations should be maintained within the age- and sex-specific normal range," the guideline states. The guideline is published in the Journal of Clinical Endocrinology and Metabolism.

The CDC's surveillance data on HIV in adolescents and young adults documents that approximately 21% of new HIV diagnoses in the United States occur in persons aged 13 to 24, underscoring the clinical relevance of pediatric HIV comorbidity management including lipodystrophy. CDC HIV surveillance data are available at cdc.gov.